CN1886379A - 苯并咪唑衍生物、含它们的组合物、其制备方法和用途 - Google Patents

苯并咪唑衍生物、含它们的组合物、其制备方法和用途 Download PDF

Info

Publication number
CN1886379A
CN1886379A CNA2004800350086A CN200480035008A CN1886379A CN 1886379 A CN1886379 A CN 1886379A CN A2004800350086 A CNA2004800350086 A CN A2004800350086A CN 200480035008 A CN200480035008 A CN 200480035008A CN 1886379 A CN1886379 A CN 1886379A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
heterocyclyl
alkenyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800350086A
Other languages
English (en)
Chinese (zh)
Inventor
刘自平
丹尼尔·佩奇
克里斯托弗·沃波尔
杨华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1886379A publication Critical patent/CN1886379A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800350086A 2003-09-26 2004-09-24 苯并咪唑衍生物、含它们的组合物、其制备方法和用途 Pending CN1886379A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302573A SE0302573D0 (sv) 2003-09-26 2003-09-26 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE03025731 2003-09-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010105277900A Division CN102010373A (zh) 2003-09-26 2004-09-24 苯并咪唑衍生物、含它们的组合物、其制备方法和用途

Publications (1)

Publication Number Publication Date
CN1886379A true CN1886379A (zh) 2006-12-27

Family

ID=29246982

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800350086A Pending CN1886379A (zh) 2003-09-26 2004-09-24 苯并咪唑衍生物、含它们的组合物、其制备方法和用途
CN2010105277900A Pending CN102010373A (zh) 2003-09-26 2004-09-24 苯并咪唑衍生物、含它们的组合物、其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010105277900A Pending CN102010373A (zh) 2003-09-26 2004-09-24 苯并咪唑衍生物、含它们的组合物、其制备方法和用途

Country Status (33)

Country Link
US (1) US8633235B2 (enExample)
EP (1) EP1670769B1 (enExample)
JP (1) JP4896721B2 (enExample)
KR (1) KR101170184B1 (enExample)
CN (2) CN1886379A (enExample)
AR (1) AR045819A1 (enExample)
AT (1) ATE430135T1 (enExample)
AU (1) AU2004276062B2 (enExample)
BR (1) BRPI0414780B8 (enExample)
CA (1) CA2539738C (enExample)
CO (1) CO5680443A2 (enExample)
CY (1) CY1110332T1 (enExample)
DE (1) DE602004020907D1 (enExample)
DK (1) DK1670769T3 (enExample)
ES (1) ES2324669T3 (enExample)
HR (1) HRP20090388T1 (enExample)
IL (1) IL174215A0 (enExample)
IS (1) IS8422A (enExample)
MX (1) MXPA06003197A (enExample)
MY (1) MY140630A (enExample)
NO (1) NO20061839L (enExample)
NZ (1) NZ545736A (enExample)
PL (1) PL1670769T3 (enExample)
PT (1) PT1670769E (enExample)
RU (1) RU2346938C2 (enExample)
SA (1) SA04250310B1 (enExample)
SE (1) SE0302573D0 (enExample)
SI (1) SI1670769T1 (enExample)
TW (1) TW200521117A (enExample)
UA (1) UA86776C2 (enExample)
UY (1) UY28536A1 (enExample)
WO (1) WO2005030732A1 (enExample)
ZA (3) ZA200602446B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
WO2006033631A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
CN101052639B (zh) * 2004-09-24 2010-10-27 阿斯利康(瑞典)有限公司 苯并咪唑衍生物、含有它们的组合物、其制备方法和其用途
JP2008514592A (ja) * 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉ
CA2586179C (en) 2004-11-02 2011-02-08 Pfizer Inc. Sulfonyl benzimidazole derivatives
US20080167488A1 (en) * 2005-07-29 2008-07-10 Astrazeneca Ab Process for the Preparation of Geminal ((Difluorocycloalkyl)Methyl) Amines
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
JP5159630B2 (ja) * 2006-09-13 2013-03-06 協和発酵キリン株式会社 縮環複素環誘導体
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
RU2454234C1 (ru) * 2011-03-16 2012-06-27 Константин Михайлович Аверин Соли 1,3-диэтилбензимидазолия - иммуностимулирующие средства и фармацевтические композиции на их основе
NZ726849A (en) * 2012-06-13 2018-06-29 Cytec Tech Corp Stabilizer compositions containing substituted chroman compounds and methods of use
EP2864291B1 (en) 2012-06-26 2016-10-05 Bayer Pharma Aktiengesellschaft N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions
CN119013276A (zh) * 2022-03-04 2024-11-22 三进制药株式会社 新型杂环化合物和包含该化合物的药物组合物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (enExample) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
WO2001012600A1 (en) 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
IL150150A0 (en) * 2000-01-14 2002-12-01 Schering Ag 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
US7329679B2 (en) * 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2004515496A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
PT1773768T (pt) 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
US20060052421A1 (en) 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
EP1797075A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands
EP1797074A4 (en) 2004-09-24 2009-04-01 Astrazeneca Ab COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF IIII
JP2008514592A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉ
EP1797070A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Compounds, compositions containing them, preparations thereof and uses thereof ii
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
JP2008514590A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用
WO2006033631A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
JP2008514594A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用ｉ
CA2586179C (en) 2004-11-02 2011-02-08 Pfizer Inc. Sulfonyl benzimidazole derivatives
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途

Also Published As

Publication number Publication date
CY1110332T1 (el) 2015-01-14
CO5680443A2 (es) 2006-09-29
JP2007506721A (ja) 2007-03-22
ZA200602446B (en) 2007-09-26
CA2539738C (en) 2011-11-22
NZ545736A (en) 2009-11-27
US8633235B2 (en) 2014-01-21
MXPA06003197A (es) 2006-06-23
BRPI0414780A (pt) 2006-11-21
ZA200702226B (en) 2009-01-28
NO20061839L (no) 2006-06-26
KR101170184B1 (ko) 2012-07-31
IL174215A0 (en) 2006-08-01
UY28536A1 (es) 2005-04-29
HK1089436A1 (en) 2006-12-01
BRPI0414780B8 (pt) 2021-05-25
ZA200702131B (en) 2008-08-27
AU2004276062A1 (en) 2005-04-07
IS8422A (is) 2006-04-21
DK1670769T3 (da) 2009-08-10
SE0302573D0 (sv) 2003-09-26
RU2346938C2 (ru) 2009-02-20
CA2539738A1 (en) 2005-04-07
CN102010373A (zh) 2011-04-13
SI1670769T1 (sl) 2009-10-31
PL1670769T3 (pl) 2009-09-30
ES2324669T3 (es) 2009-08-12
AU2004276062B2 (en) 2008-05-22
BRPI0414780B1 (pt) 2018-10-23
UA86776C2 (ru) 2009-05-25
EP1670769B1 (en) 2009-04-29
SA04250310B1 (ar) 2009-01-19
US20080207612A1 (en) 2008-08-28
RU2006113371A (ru) 2007-11-10
TW200521117A (en) 2005-07-01
KR20070001052A (ko) 2007-01-03
DE602004020907D1 (de) 2009-06-10
PT1670769E (pt) 2009-07-09
JP4896721B2 (ja) 2012-03-14
AR045819A1 (es) 2005-11-16
HRP20090388T1 (hr) 2009-08-31
MY140630A (en) 2010-01-15
WO2005030732A1 (en) 2005-04-07
ATE430135T1 (de) 2009-05-15
EP1670769A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
CN1083431C (zh) 新的杂环化合物
CN1805956A (zh) 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途
CN1045580A (zh) 吡咯烷衍生物
JP4896721B2 (ja) ベンゾイミダゾール誘導体、それを含む組成物、その製造方法およびその使用
CN1993325A (zh) 作为组胺h3受体配体的哌啶衍生物
CN1805940A (zh) 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途
CN100349874C (zh) 新型化合物
WO2006033628A1 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CN1041088C (zh) 光学活性咪唑烷酮衍生物和抗痴呆药物组合物
CN1926122A (zh) 二芳基甲基哌嗪衍生物及其制备并用途
CN1090629C (zh) 新的杂环化合物
WO2006033633A1 (en) Compounds, compositions containing them, preparations thereof and uses thereof ii
CN1304409A (zh) 用于治疗抑郁症的吲哚－3－基－环己胺衍生物(5－ht1受体拮抗剂)
HK1101576A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CN1956959A (zh) 治疗化合物：吡啶n氧化物支架
CN1466573A (zh) 5-苯基苄胺化合物、其制备方法以及其合成中间体
CN1946721A (zh) 吡咯并喹啉和哌啶并喹啉衍生物及其制备，含有它们的组合物以及其用途
CN1173177A (zh) 6－甲氧基－1h－苯并三唑－5－甲酰胺衍生物、其制造方法及含有该衍生物的医药组合物
EP1797074A1 (en) Compounds, compositions containing them, preparation thereof and uses thereof iiii
WO2006033632A1 (en) Benzimidazole derivatives and their use as cannabinoid receptor ligands I
CN101031563A (zh) 苯并咪唑衍生物、含有它们的组合物、其制备方法和用途
CN1036711C (zh) 咪唑并中氮茚衍生物的制备方法
JP2025537921A (ja) オキシトシン受容体の非ペプチドアゴニスト
CN1926106A (zh) 二芳基亚甲基哌啶衍生物、其制备方法及其用途
CN101052637A (zh) 苯并咪唑衍生物以及它们作为大麻素受体配体i的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1101576

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20061227

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1101576

Country of ref document: HK